BackgroundMigraine is one of the most prevalent chronic pain manifestations of childhood. Despite the multitude of available treatments, parents are often concerned about chronic therapies and pediatricians have insufficient confidence in prescribing prophylactic drugs. Therefore, there is now growing interest for natural supplements used to control recurrent migraine headaches. Such approach may increase acceptance and adherence to long-term prophylaxis therapy in children.MethodsThis is an observational multicenter study performed in children (n=91) with migraine, with (MO) or without aura (MA), or tension-type headache (TTH). A fixed-dose Andrographis paniculata, CoQ10, riboflavin, and magnesium, was administered for 16weeks. Patients were evaluated at baseline (T0), at week 8 (T1) and at the end of treatment at week 16 (T2). A follow-up period occurred at week 20 (T3) and week 32 (T4).ResultsThe herbal supplement significantly reduced the frequency of headaches in TTH patients during treatment period (T0: 11.97+1.92 vs T2: 5.13+1.93; p<0.001) and the efficacy was maintained after 16weeks of treatment withdrawal (T4: 4.46+1.75; p<0.001 vs T0). The frequency of migraine attacks was also reduced in the MO group during treatment (T0: 9.70+0.96 vs T2: 4.03+0.75; p<0.01) and after withdrawal (T4: 2.96+0.65; p<0.01 vs T0). Conversely, MA patients showed reduction in migraine's frequency during treatment (T0: 8.74+1.91 vs T2: 3.78+2.02; p<0.01) but not at the end of the study (T4: 5.57+3.31; p>0.05 vs T0).TTH patients did not report significant improvement of pain intensity. A significant effect was observed in the MO group during treatment (T0: 3.06+0.11 vs T2: 2.14+0.19; p<0.001) and after treatment withdrawal (T4: 2.20+0.21; p<0.001 vs T0). Likewise, MA group showed a significant treatment effect (T0: 2.57+0.20 vs T2: 0.86+0.45; p<0.001) and the efficacy persisted at the end of the study (T4: 1.00+0.58; p<0.001 vs T0).ConclusionThis fixed-dose Tanacetum parthenium preparation improved headache frequency and pain intensity in children affected by TTH. Despite the main limits, this study supports the use of nutraceutical in pediatric headache/migraine.

An observational study of fixed-dose Tanacetum parthenium nutraceutical preparation for prophylaxis of pediatric headache / Moscano, F.; Guiducci, Michela; Maltoni, L.; Striano, P.; Ledda, M. G.; Zoroddu, F.; Raucci, U.; Villa, M. P.; Parisi, P.. - In: THE ITALIAN JOURNAL OF PEDIATRICS. - ISSN 1720-8424. - 45:1(2019), pp. 1-6. [10.1186/s13052-019-0624-z]

An observational study of fixed-dose Tanacetum parthenium nutraceutical preparation for prophylaxis of pediatric headache

Guiducci, Michela;Villa M. P.;Parisi P.
Ultimo
Writing – Original Draft Preparation
2019

Abstract

BackgroundMigraine is one of the most prevalent chronic pain manifestations of childhood. Despite the multitude of available treatments, parents are often concerned about chronic therapies and pediatricians have insufficient confidence in prescribing prophylactic drugs. Therefore, there is now growing interest for natural supplements used to control recurrent migraine headaches. Such approach may increase acceptance and adherence to long-term prophylaxis therapy in children.MethodsThis is an observational multicenter study performed in children (n=91) with migraine, with (MO) or without aura (MA), or tension-type headache (TTH). A fixed-dose Andrographis paniculata, CoQ10, riboflavin, and magnesium, was administered for 16weeks. Patients were evaluated at baseline (T0), at week 8 (T1) and at the end of treatment at week 16 (T2). A follow-up period occurred at week 20 (T3) and week 32 (T4).ResultsThe herbal supplement significantly reduced the frequency of headaches in TTH patients during treatment period (T0: 11.97+1.92 vs T2: 5.13+1.93; p<0.001) and the efficacy was maintained after 16weeks of treatment withdrawal (T4: 4.46+1.75; p<0.001 vs T0). The frequency of migraine attacks was also reduced in the MO group during treatment (T0: 9.70+0.96 vs T2: 4.03+0.75; p<0.01) and after withdrawal (T4: 2.96+0.65; p<0.01 vs T0). Conversely, MA patients showed reduction in migraine's frequency during treatment (T0: 8.74+1.91 vs T2: 3.78+2.02; p<0.01) but not at the end of the study (T4: 5.57+3.31; p>0.05 vs T0).TTH patients did not report significant improvement of pain intensity. A significant effect was observed in the MO group during treatment (T0: 3.06+0.11 vs T2: 2.14+0.19; p<0.001) and after treatment withdrawal (T4: 2.20+0.21; p<0.001 vs T0). Likewise, MA group showed a significant treatment effect (T0: 2.57+0.20 vs T2: 0.86+0.45; p<0.001) and the efficacy persisted at the end of the study (T4: 1.00+0.58; p<0.001 vs T0).ConclusionThis fixed-dose Tanacetum parthenium preparation improved headache frequency and pain intensity in children affected by TTH. Despite the main limits, this study supports the use of nutraceutical in pediatric headache/migraine.
2019
nutraceuticals; observational study; pediatric migraine; prophylaxis; tanacetum parthenium; adolescent; analysis of variance; child; cohort studies; female; follow-up studies; holistic health; humans; italy; magnesium; male; migraine disorders; pain measurement; plant extracts; plants; medicinal; prospective studies; riboflavin; risk assessment; severity of illness index; statistics; nonparametric; tension-type headache; treatment outcome; ubiquinone; dietary supplements; tanacetum parthenium
01 Pubblicazione su rivista::01a Articolo in rivista
An observational study of fixed-dose Tanacetum parthenium nutraceutical preparation for prophylaxis of pediatric headache / Moscano, F.; Guiducci, Michela; Maltoni, L.; Striano, P.; Ledda, M. G.; Zoroddu, F.; Raucci, U.; Villa, M. P.; Parisi, P.. - In: THE ITALIAN JOURNAL OF PEDIATRICS. - ISSN 1720-8424. - 45:1(2019), pp. 1-6. [10.1186/s13052-019-0624-z]
File allegati a questo prodotto
File Dimensione Formato  
Moscano_observational_2019.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 633.59 kB
Formato Adobe PDF
633.59 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1326156
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 14
social impact